HomeADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
Previous close
$0.62
Day range
$0.57 - $0.63
Year range
$0.53 - $2.05
Market cap
158.62M USD
Avg Volume
2.43M
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 40.90M | 458.83% |
Operating expense | 21.28M | 31.63% |
Net income | -17.62M | 61.37% |
Net profit margin | -43.07 | 93.09% |
Earnings per share | -0.01 | 70.15% |
EBITDA | -11.86M | 72.88% |
Effective tax rate | -4.95% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 186.09M | 15.06% |
Total assets | 317.44M | 7.01% |
Total liabilities | 237.45M | 13.88% |
Total equity | 79.99M | — |
Shares outstanding | 255.88M | — |
Price to book | 2.00 | — |
Return on assets | -11.48% | — |
Return on capital | -24.62% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -17.62M | 61.37% |
Cash from operations | -54.45M | -20.58% |
Cash from investing | -66.02M | -215.20% |
Cash from financing | 25.00M | 4,094.80% |
Net change in cash | -95.25M | -840.01% |
Free cash flow | -41.07M | -62.70% |
About
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Founded
2008
Website
Employees
449
